Metabolic Syndrome, Diabetes, and Cardiovascular Risk in HIV

被引:66
|
作者
Nix, Linda M. [1 ,2 ]
Tien, Phyllis C. [3 ,4 ]
机构
[1] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA
[2] UCSF, No Calif Inst Res & Educ, San Francisco, CA 94122 USA
[3] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[4] Dept Vet Affairs Med Ctr, Med Serv, San Francisco, CA 94121 USA
关键词
HIV; Metabolic syndrome; Diabetes; Cardiovascular risk; Framingham risk score; Lipodystrophy syndrome; ANTIRETROVIRAL THERAPY EXPOSURE; CHOLESTERYL ESTER TRANSFER; CORONARY-HEART-DISEASE; INFECTED PATIENTS; INSULIN-RESISTANCE; NATIONAL-HEALTH; NAIVE INDIVIDUALS; DATA-COLLECTION; MELLITUS; PREVALENCE;
D O I
10.1007/s11904-014-0219-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
HIV infection and its treatment have been associated with adipose tissue changes and disorders of glucose and lipid metabolism. The proportion of HIV-infected adults over the age of 50 is also growing placing HIV-infected adults at particular risk for metabolic perturbations and cardiovascular disease. The metabolic syndrome in HIV-infected adults has been increasingly studied but whether HIV is associated with greater risk remains unclear, likely because of the interplay of host, viral and antiretroviral factors that are associated with the components of the metabolic syndrome. The relationship between HIV and diabetes mellitus (DM) risk has also been debated. While the Framingham Risk Score is a well-accepted measure of 10-year cardiovascular risk in the general population, it may not accurately predict risk in the HIV setting due to HIV-related factors such as inflammation that are not accounted for. We summarize the recent literature on metabolic syndrome, DM, and cardiovascular risk in HIV-infected adults.
引用
收藏
页码:271 / 278
页数:8
相关论文
共 50 条
  • [1] Metabolic Syndrome, Diabetes, and Cardiovascular Risk in HIV
    Linda M. Nix
    Phyllis C. Tien
    Current HIV/AIDS Reports, 2014, 11 : 271 - 278
  • [2] HIV Therapy, Metabolic Syndrome, and Cardiovascular Risk
    Pao, Vivian
    Lee, Grace A.
    Grunfeld, Carl
    CURRENT ATHEROSCLEROSIS REPORTS, 2008, 10 (01) : 61 - 70
  • [3] Infection by HIV, metabolic syndrome and cardiovascular risk
    Pedro-Botet, Juan
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2009, 21 (02): : 68 - 70
  • [4] HIV therapy, metabolic syndrome, and cardiovascular risk
    Vivian Pao
    Grace A. Lee
    Carl Grunfeld
    Current Atherosclerosis Reports, 2008, 10 : 61 - 70
  • [5] COMPREHENSIVE CARDIOVASCULAR RISK REDUCTION IN THE METABOLIC SYNDROME AND DIABETES
    Sperling, L. S.
    CARDIOLOGY, 2016, 134 : 83 - 83
  • [6] Pre-Diabetes, Metabolic Syndrome, and Cardiovascular Risk
    Grundy, Scott M.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (07) : 635 - 643
  • [7] Type 1 diabetes, metabolic syndrome and cardiovascular risk
    Chillaron, Juan J.
    Flores Le-Roux, Juana A.
    Benaiges, David
    Pedro-Botet, Juan
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2014, 63 (02): : 181 - 187
  • [8] Metabolic syndrome risk for cardiovascular disease and diabetes in the ARIC study
    C M Ballantyne
    R C Hoogeveen
    A M McNeill
    G Heiss
    M I Schmidt
    B B Duncan
    J S Pankow
    International Journal of Obesity, 2008, 32 : S21 - S24
  • [9] Metabolic syndrome risk for cardiovascular disease and diabetes in the ARIC study
    Ballantyne, C. M.
    Hoogeveen, R. C.
    McNeill, A. M.
    Heiss, G.
    Schmidt, M. I.
    Duncan, B. B.
    Pankow, J. S.
    INTERNATIONAL JOURNAL OF OBESITY, 2008, 32 (Suppl 2) : S21 - S24
  • [10] Focus on type 2 diabetes, metabolic syndrome and cardiovascular risk
    POST ACCORD PERSPECTIVES: THE ROLE OF FENOFIBRATES: TRANSLATING THE EVIDENCE-BASED MEDICINE AND SCIENCE INTO CLINICAL PRACTICE FOR THE PRIMARY CARE PROVIDER, 2010, 274 : 20 - 25